Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1161/JAHA.116.003221 http://scihub22266oqcxt.onion/10.1161/JAHA.116.003221 C4889192!4889192!27153871     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27153871&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Heart+Assoc 2016 ; 5 (5): ä Nephropedia Template TP {{tp|p=27153871|t=2016. Cost?Effectiveness of Ivabradine for Heart Failure in the United States |pdf=|usr=}}{{27153871}} gab.com Text Cost Effectiveness of Ivabradine for Heart Failure in the United States JO: J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=27153871 #FOAvip Background: Ivabradine is a heart rate?lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost?effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage payer. Methods and Results: A cost?effectiveness, cohort?based Markov model using a state transition approach tracked a cohort of heart failure patients with heart rate ?70 beats per minute in sinus rhythm who were treated with ivabradine+background therapy or background therapy alone. Model inputs, including adjusted hazard ratios, rates of hospitalization and mortality, adverse events, and utility?regression equations, were derived from a large US claims database and SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial). In the commercial population, ivabradine+background therapy was associated with a cost savings of $8594 versus the cost of background therapy alone over a 10?year time horizon, primarily because of reduced hospitalization. Ivabradine was associated with an incremental benefit of 0.24 quality?adjusted life years over a 10?year time horizon. In the Medicare Advantage population, the incremental cost?effectiveness ratio for ivabradine was estimated to be $24 920/quality?adjusted life years. Conclusions: The cost?effectiveness model suggests that for a commercial population, the addition of ivabradine to background therapy was associated with cost savings and improved clinical outcomes. For a Medicare Advantage population, the analysis indicates that the clinical benefit of ivabradine can be achieved at a reasonable cost. Twit Text FOAVip Cost Effectiveness of Ivabradine for Heart Failure in the United States ????J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=27153871 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27153871 #FOAvip English Wikipedia <ref>{{Cite pmid|27153871}}</ref> Cost?Effectiveness of Ivabradine for Heart Failure in the United States #MMPMID27153871 Kansal AR; Cowie MR; Kielhorn A; Krotneva S; Tafazzoli A; Zheng Y; Yurgin N J Am Heart Assoc 2016[May]; 5 (5): ä PMID27153871show ga Background: Ivabradine is a heart rate?lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost?effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage payer. Methods and Results: A cost?effectiveness, cohort?based Markov model using a state transition approach tracked a cohort of heart failure patients with heart rate ?70 beats per minute in sinus rhythm who were treated with ivabradine+background therapy or background therapy alone. Model inputs, including adjusted hazard ratios, rates of hospitalization and mortality, adverse events, and utility?regression equations, were derived from a large US claims database and SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial). In the commercial population, ivabradine+background therapy was associated with a cost savings of $8594 versus the cost of background therapy alone over a 10?year time horizon, primarily because of reduced hospitalization. Ivabradine was associated with an incremental benefit of 0.24 quality?adjusted life years over a 10?year time horizon. In the Medicare Advantage population, the incremental cost?effectiveness ratio for ivabradine was estimated to be $24 920/quality?adjusted life years. Conclusions: The cost?effectiveness model suggests that for a commercial population, the addition of ivabradine to background therapy was associated with cost savings and improved clinical outcomes. For a Medicare Advantage population, the analysis indicates that the clinical benefit of ivabradine can be achieved at a reasonable cost. äCost?Effectiveness of Ivabradine for Heart Failure in the United State(epmc).pdf DeepDyve Pubget Overpricing